The abstract is read at the publisher; the summary is JClub's.
Intismeran plus pembrolizumab sustained improved recurrence-free survival in resected stage IIIB–IV cutaneous melanoma, with HR 0.510 at 5 years versus pembrolizumab alone.
- Why it matters: High-risk resected melanoma still recurs and metastasizes despite adjuvant pembrolizumab, so longer-term evidence is needed to confirm durable benefit and safety.
- What they did: In KEYNOTE-942 (NCT03897881), 157 randomized patients received nine doses of intramuscular intismeran 1 mg every 3 weeks plus 18 doses of intravenous pembrolizumab 200 mg every 3 weeks, or pembrolizumab alone; 5-year analyses were descriptive.
- The result: At data cutoff (December 15, 2025), the combination also prolonged distant metastasis-free survival (HR 0.411) with manageable safety and increased T-cell receptor clonality and novel clonotypes versus pembrolizumab.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.